{"transactions":[{"id":681751,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21731,"kind":"person","name":"Peoples George","position":1,"cik":"0002029803","reported_name":"Peoples George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-08-19T23:00:15.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include the stock options previously granted to the Reporting Person."}],"balance_after":4000,"derivative":{"exercise_price":1.36,"expiration_date":"2036-08-17","underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001493152-26-039292","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2029803/000149315226039292/ownership.xml","form_type":"4"}},{"id":681677,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-08-19T23:00:13.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include the stock options previously granted to the Reporting Person."}],"balance_after":4000,"derivative":{"exercise_price":1.36,"expiration_date":"2036-08-17","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001493152-26-039290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000149315226039290/ownership.xml","form_type":"4"}},{"id":681559,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21680,"kind":"person","name":"Stewart Alan R.","position":1,"cik":"0001705492","reported_name":"Stewart Alan R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-08-19T23:00:12.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include the stock options previously granted to the Reporting Person."}],"balance_after":4000,"derivative":{"exercise_price":1.36,"expiration_date":"2036-08-17","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001493152-26-039291","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226039291/ownership.xml","form_type":"4"}},{"id":681558,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21679,"kind":"person","name":"Jackson Andrew C.","position":1,"cik":"0001636738","reported_name":"Jackson Andrew C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2026-08-19T23:00:10.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on August 17, 2026 (the \"Grant Date\"), the Reporting Person was granted 14,000 incentive stock options (the \"Options\") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include the incentive stock options previously granted to the Reporting Person."}],"balance_after":14000,"derivative":{"exercise_price":1.36,"exercise_date":"2026-08-17","expiration_date":"2036-08-17","underlying":"Common stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001493152-26-039289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226039289/ownership.xml","form_type":"4"}},{"id":681557,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-08-19T23:00:08.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 5,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 5,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include the stock options previously granted to the Reporting Person."}],"balance_after":5000,"derivative":{"exercise_price":1.36,"expiration_date":"2036-08-17","underlying":"Common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001493152-26-039288","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226039288/ownership.xml","form_type":"4"}},{"id":681556,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21677,"kind":"person","name":"Poma Eric E","position":1,"cik":"0001339484","reported_name":"Poma Eric E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2026-08-19T23:00:07.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":32000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on August 17, 2026 (the \"Grant Date\"), the Reporting Person was granted 32,000 incentive stock options (the \"Options\") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include the incentive stock options previously granted to the Reporting Person."}],"balance_after":32000,"derivative":{"exercise_price":1.36,"exercise_date":"2026-08-17","expiration_date":"2036-08-17","underlying":"Common stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001493152-26-039287","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226039287/ownership.xml","form_type":"4"}},{"id":681555,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21676,"kind":"person","name":"Fernandez Santidrian Antonio","position":1,"cik":"0001990403","reported_name":"Fernandez Santidrian Antonio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2026-08-19T23:00:05.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on August 17, 2026 (the \"Grant Date\"), the Reporting Person was granted 16,000 incentive stock options (the \"Options\") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include the incentive stock options previously granted to the Reporting Person."}],"balance_after":16000,"derivative":{"exercise_price":1.36,"exercise_date":"2026-08-17","expiration_date":"2036-08-17","underlying":"Common stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001493152-26-039286","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226039286/ownership.xml","form_type":"4"}},{"id":681554,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21675,"kind":"person","name":"Sanders Corazon (Corsee) D.","position":1,"cik":"0001796536","reported_name":"Sanders Corazon (Corsee) D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-08-19T23:00:03.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include the stock options previously granted to the Reporting Person."}],"balance_after":6000,"derivative":{"exercise_price":1.36,"expiration_date":"2036-08-17","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001493152-26-039285","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226039285/ownership.xml","form_type":"4"}},{"id":967741,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-17T00:37:06.000Z","date":"2025-12-12","kind":"sale","planned":false,"acquired":false,"shares":850,"price":1.455,"value":1236.75,"ownership":{"direct":false,"nature":"AJC Capital, LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"All share and share related information gives retrospective effect to the 1-for-12 reverse stock split effective on August 4, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected for estate and tax planning purposes by AJC Capital, LLC (\"AJC\"). The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 6,394 shares of Common Stock directly held by Allan Camaisa, (ii) 19,860 shares of Common Stock held by AJC, and (iii) 50,698 shares of Common Stock held by Jamir Trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Does not include, (i) 1,526 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by Mr. Camaisa, (ii) 3,915 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, and (iii) 22,887 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by AJC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa is deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa is deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust."}],"balance_after":76952,"source":{"system":"sec-edgar","filing":"0001493152-25-028030","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315225028030/ownership.xml","form_type":"4"}},{"id":1046891,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21677,"kind":"person","name":"Poma Eric E","position":1,"cik":"0001339484","reported_name":"Poma Eric E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2025-09-05T23:56:29.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on September 3, 2025 (the \"Grant Date\"), the Reporting Person was granted 10,000 incentive stock options (the \"Options\") at an exercise price of $1.58, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 9/03/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":10000,"derivative":{"exercise_price":1.58,"exercise_date":"2025-09-03","expiration_date":"2035-09-03","underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001641172-25-026782","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225026782/ownership.xml","form_type":"4"}},{"id":1046888,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21676,"kind":"person","name":"Fernandez Santidrian Antonio","position":1,"cik":"0001990403","reported_name":"Fernandez Santidrian Antonio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2025-09-05T23:56:27.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on September 3, 2025 (the \"Grant Date\"), the Reporting Person was granted 35,000 incentive stock options (the \"Options\") at an exercise price of $1.58, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 9/03/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":35000,"derivative":{"exercise_price":1.58,"exercise_date":"2025-09-03","expiration_date":"2035-09-03","underlying":"Common stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001641172-25-026780","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225026780/ownership.xml","form_type":"4"}},{"id":1046886,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21679,"kind":"person","name":"Jackson Andrew C.","position":1,"cik":"0001636738","reported_name":"Jackson Andrew C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2025-09-05T23:56:26.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on September 3, 2025 (the \"Grant Date\"), the Reporting Person was granted 30,000 incentive stock options (the \"Options\") at an exercise price of $1.58, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 9/03/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":30000,"derivative":{"exercise_price":1.58,"exercise_date":"2025-09-03","expiration_date":"2035-09-03","underlying":"Common stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001641172-25-026781","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225026781/ownership.xml","form_type":"4"}},{"id":1056886,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2025-08-26T00:47:41.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":75000,"derivative":{"exercise_price":2,"exercise_date":"2025-08-21","expiration_date":"2030-08-21","underlying":"Common stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001641172-25-025448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225025448/ownership.xml","form_type":"4"}},{"id":1056885,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T00:47:41.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":2,"value":150000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":76134,"source":{"system":"sec-edgar","filing":"0001641172-25-025448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225025448/ownership.xml","form_type":"4"}},{"id":1056891,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21677,"kind":"person","name":"Poma Eric E","position":1,"cik":"0001339484","reported_name":"Poma Eric E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2025-08-26T00:47:39.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":25000,"derivative":{"exercise_price":2,"exercise_date":"2025-08-21","expiration_date":"2030-08-21","underlying":"Common stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001641172-25-025447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225025447/ownership.xml","form_type":"4"}},{"id":1056890,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21677,"kind":"person","name":"Poma Eric E","position":1,"cik":"0001339484","reported_name":"Poma Eric E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-26T00:47:39.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":2,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001641172-25-025447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225025447/ownership.xml","form_type":"4"}},{"id":1056934,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2025-08-26T00:47:37.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":125000,"derivative":{"exercise_price":2,"exercise_date":"2025-08-21","expiration_date":"2030-08-21","underlying":"Common stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001641172-25-025446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000164117225025446/ownership.xml","form_type":"4"}},{"id":1056933,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T00:47:37.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":125000,"price":2,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":130650,"source":{"system":"sec-edgar","filing":"0001641172-25-025446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000164117225025446/ownership.xml","form_type":"4"}},{"id":1056883,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21679,"kind":"person","name":"Jackson Andrew C.","position":1,"cik":"0001636738","reported_name":"Jackson Andrew C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrant (right to buy)","published_at":"2025-08-26T00:47:36.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":2500,"derivative":{"exercise_price":2,"exercise_date":"2025-08-21","expiration_date":"2030-08-21","underlying":"Common stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001641172-25-025445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225025445/ownership.xml","form_type":"4"}},{"id":1056882,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21679,"kind":"person","name":"Jackson Andrew C.","position":1,"cik":"0001636738","reported_name":"Jackson Andrew C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-26T00:47:36.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":2,"value":5000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001641172-25-025445","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225025445/ownership.xml","form_type":"4"}},{"id":1087410,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2025-07-16T00:42:59.000Z","date":"2025-07-09","kind":"grant","planned":false,"acquired":true,"shares":164493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 164,493 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 164,493 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."}],"balance_after":164493,"derivative":{"exercise_price":0.7,"expiration_date":"2035-07-09","underlying":"Common stock","underlying_shares":164493},"source":{"system":"sec-edgar","filing":"0001641172-25-019802","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225019802/ownership.xml","form_type":"4"}},{"id":1087409,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21680,"kind":"person","name":"Stewart Alan R.","position":1,"cik":"0001705492","reported_name":"Stewart Alan R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2025-07-16T00:42:57.000Z","date":"2025-07-09","kind":"grant","planned":false,"acquired":true,"shares":137078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."}],"balance_after":137078,"derivative":{"exercise_price":0.7,"expiration_date":"2035-07-09","underlying":"Common Stock","underlying_shares":137078},"source":{"system":"sec-edgar","filing":"0001641172-25-019803","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225019803/ownership.xml","form_type":"4"}},{"id":1087450,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21731,"kind":"person","name":"Peoples George","position":1,"cik":"0002029803","reported_name":"Peoples George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2025-07-16T00:42:56.000Z","date":"2025-07-09","kind":"grant","planned":false,"acquired":true,"shares":137078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."}],"balance_after":137078,"derivative":{"exercise_price":0.7,"expiration_date":"2035-07-09","underlying":"Common stock","underlying_shares":137078},"source":{"system":"sec-edgar","filing":"0001641172-25-019801","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2029803/000164117225019801/ownership.xml","form_type":"4"}},{"id":1087431,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2025-07-16T00:42:54.000Z","date":"2025-07-09","kind":"grant","planned":false,"acquired":true,"shares":137078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."}],"balance_after":137078,"derivative":{"exercise_price":0.7,"expiration_date":"2035-07-09","underlying":"Common Stock","underlying_shares":137078},"source":{"system":"sec-edgar","filing":"0001641172-25-019800","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000164117225019800/ownership.xml","form_type":"4"}},{"id":1165756,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21677,"kind":"person","name":"Poma Eric E","position":1,"cik":"0001339484","reported_name":"Poma Eric E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-25T10:05:05.000Z","date":"2025-04-22","kind":"grant","planned":false,"acquired":true,"shares":726412,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 22, 2025 (the \"Grant Date\"), the compensation committee and board of directors of Calidi Biotherapeutics, Inc. (\"Issuer\") approved an inducement grant to the Reporting Person of 726,412 stock options (the \"Options\"), pursuant to the exception under Section 711 NYSE American, at a per share exercise price of $0.4690, which is equal to the closing price of the Issuer's common stock on the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"25% of the options will vest upon the one (1) year anniversary of 04/22/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 22, 2025 (the \"Grant Date\"), the compensation committee and board of directors of Calidi Biotherapeutics, Inc. (\"Issuer\") approved an inducement grant to the Reporting Person of 726,412 stock options (the \"Options\"), pursuant to the exception under Section 711 NYSE American, at a per share exercise price of $0.4690, which is equal to the closing price of the Issuer's common stock on the Grant Date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"25% of the options will vest upon the one (1) year anniversary of 04/22/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer."}],"balance_after":726412,"derivative":{"exercise_price":0.469,"expiration_date":"2035-04-22","underlying":"Common Stock","underlying_shares":726412},"source":{"system":"sec-edgar","filing":"0001641172-25-006070","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225006070/ownership.xml","form_type":"4"}},{"id":1315179,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21680,"kind":"person","name":"Stewart Alan R.","position":1,"cik":"0001705492","reported_name":"Stewart Alan R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T22:27:37.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":12771,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on December 31, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with a payment in lieu of cash for services during the Issuer's fourth fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date. The price per share at which the grants were issued is $1.15 and was determined based on the Issuer's closing price on December 31, 2024."}],"balance_after":28976,"source":{"system":"sec-edgar","filing":"0001493152-25-000306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315225000306/ownership.xml","form_type":"4"}},{"id":1315481,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T22:25:58.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":11684,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on December 31, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with a payment in lieu of cash for services during the Issuer's fourth fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date. The price per share at which the grants were issued is $1.15 and was determined based on the Issuer's closing price on December 31, 2024."}],"balance_after":67774,"source":{"system":"sec-edgar","filing":"0001493152-25-000302","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000149315225000302/ownership.xml","form_type":"4"}},{"id":1326858,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Stock","published_at":"2024-12-19T02:29:33.000Z","date":"2024-12-17","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":1.62,"value":16200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected for tax planning purposes. The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,557 shares of Common Stock directly held by Allan Camaisa. Does not include (i) 14,000 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2023 Equity Plan, (ii) 6,445 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2019 Equity Plan, (iii) 46,972 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, (iv) 70,760 shares of Common Stock issuable upon exercise of options held by AJC Capital, LLC (\"AJC\"), (v) 203,954 shares of Common Stock issuable upon exercise of options held by AJC, (vi) 281,513 shares of Common Stock held by AJC, and (vii) 608,383 shares of Common Stock held by Jamir Trust. Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa may be deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust."}],"balance_after":66712,"source":{"system":"sec-edgar","filing":"0001493152-24-050675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224050675/ownership.xml","form_type":"4"}},{"id":1386788,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-10-16T01:14:37.000Z","date":"2024-09-20","kind":"grant","planned":false,"acquired":true,"shares":20217,"ownership":{"direct":true},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."}],"balance_after":20217,"derivative":{"exercise_price":1.09,"expiration_date":"2034-09-20","underlying":"Common stock","underlying_shares":20217},"source":{"system":"sec-edgar","filing":"0001493152-24-041199","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000149315224041199/ownership.xml","form_type":"4"}},{"id":1386813,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21731,"kind":"person","name":"Peoples George","position":1,"cik":"0002029803","reported_name":"Peoples George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-10-16T01:14:36.000Z","date":"2024-09-20","kind":"grant","planned":false,"acquired":true,"shares":20217,"ownership":{"direct":true},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."}],"balance_after":20217,"derivative":{"exercise_price":1.09,"expiration_date":"2034-09-20","underlying":"Common stock","underlying_shares":20217},"source":{"system":"sec-edgar","filing":"0001493152-24-041200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2029803/000149315224041200/ownership.xml","form_type":"4"}},{"id":1386745,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-10-16T01:14:35.000Z","date":"2024-09-20","kind":"grant","planned":false,"acquired":true,"shares":20217,"ownership":{"direct":true},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."}],"balance_after":20217,"derivative":{"exercise_price":1.09,"expiration_date":"2034-09-20","underlying":"Common stock","underlying_shares":20217},"source":{"system":"sec-edgar","filing":"0001493152-24-041201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224041201/ownership.xml","form_type":"4"}},{"id":1386744,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21680,"kind":"person","name":"Stewart Alan R.","position":1,"cik":"0001705492","reported_name":"Stewart Alan R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-10-16T01:14:34.000Z","date":"2024-09-20","kind":"grant","planned":false,"acquired":true,"shares":20217,"ownership":{"direct":true},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."}],"balance_after":20217,"derivative":{"exercise_price":1.09,"expiration_date":"2034-09-20","underlying":"Common stock","underlying_shares":20217},"source":{"system":"sec-edgar","filing":"0001493152-24-041202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224041202/ownership.xml","form_type":"4"}},{"id":1397970,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Stock","published_at":"2024-09-30T22:53:38.000Z","date":"2024-09-26","kind":"grant","planned":false,"acquired":true,"shares":70155,"price":1.15,"value":80678.25,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"In lieu of cash repayments for payables owed to Mr. Camaisa, 70,155 shares were issued to the reporting person at a price per share of $1.15, the closing price of the issuer's common stock immediately prior to the issuance date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Includes 6,557 shares of Common Stock directly held by Allan Camaisa. Does not include (i) 14,000 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2023 Equity Plan, (ii) 6,445 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2019 Equity Plan, (iii) 46,972 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, (iv) 70,760 shares of Common Stock issuable upon exercise of options held by AJC Capital, LLC (\"AJC\"), (v) 203,954 shares of Common Stock issuable upon exercise of options held by AJC, (vi) 281,513 shares of Common Stock held by AJC, and (vii) 608,383 shares of Common Stock held by Jamir Trust. Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa may be deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust."}],"balance_after":76712,"source":{"system":"sec-edgar","filing":"0001493152-24-038877","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224038877/ownership.xml","form_type":"4"}},{"id":1456378,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21731,"kind":"person","name":"Peoples George","position":1,"cik":"0002029803","reported_name":"Peoples George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-07-11T20:53:47.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":30904,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on July 1, 2024 (the \"Grant Date\"), the Reporting Person was granted 30,904 non-qualified stock options (the \"Options\") at the exercise price of $0.193, which is the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/36 per month over three years, commencing on the Grant Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on July 1, 2024 (the \"Grant Date\"), the Reporting Person was granted 30,904 non-qualified stock options (the \"Options\") at the exercise price of $0.193, which is the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/36 per month over three years, commencing on the Grant Date."}],"balance_after":30904,"derivative":{"exercise_price":0.193,"expiration_date":"2034-07-01","underlying":"Common stock","underlying_shares":30904},"source":{"system":"sec-edgar","filing":"0001493152-24-026971","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2029803/000149315224026971/ownership.xml","form_type":"4"}},{"id":1463516,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T00:22:46.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":67187,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on June 28, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's second fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date."}],"balance_after":560873,"source":{"system":"sec-edgar","filing":"0001493152-24-026117","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000149315224026117/ownership.xml","form_type":"4"}},{"id":1463322,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T00:20:57.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":79687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on June 28, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's second fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date."}],"balance_after":1071781,"source":{"system":"sec-edgar","filing":"0001493152-24-026115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224026115/ownership.xml","form_type":"4"}},{"id":1463321,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21680,"kind":"person","name":"Stewart Alan R.","position":1,"cik":"0001705492","reported_name":"Stewart Alan R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T00:18:58.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":73437,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on June 28, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's second fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date."}],"balance_after":154087,"source":{"system":"sec-edgar","filing":"0001493152-24-026113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224026113/ownership.xml","form_type":"4"}},{"id":1463515,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T00:16:42.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":23783,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on March 29, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's first fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date."}],"balance_after":493686,"source":{"system":"sec-edgar","filing":"0001493152-24-026111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000149315224026111/ownership.xml","form_type":"4"}},{"id":1463320,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T00:14:26.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":28207,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on March 29, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's first fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date."}],"balance_after":992094,"source":{"system":"sec-edgar","filing":"0001493152-24-026108","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224026108/ownership.xml","form_type":"4"}},{"id":1463319,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21680,"kind":"person","name":"Stewart Alan R.","position":1,"cik":"0001705492","reported_name":"Stewart Alan R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T00:12:36.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":25995,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on March 29, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's first fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date."}],"balance_after":80650,"source":{"system":"sec-edgar","filing":"0001493152-24-026105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224026105/ownership.xml","form_type":"4"}},{"id":1473367,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Stock Options (right to buy)","published_at":"2024-06-21T00:56:05.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.215, which is equal to 110% of the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.215, which is equal to 110% of the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":40000,"derivative":{"exercise_price":0.215,"expiration_date":"2029-06-17","underlying":"Common stock"},"source":{"system":"sec-edgar","filing":"0001493152-24-024597","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224024597/ownership.xml","form_type":"4"}},{"id":1473366,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":89728,"kind":"person","name":"Campbell Wendy Pizarro","position":1,"cik":"0001990445","reported_name":"Campbell Wendy Pizarro","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Admin. and Legal Officer"}}],"security":"Stock Options (right to buy)","published_at":"2024-06-21T00:56:02.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Issuer's 2023 Plan, on the Grant Date, the Reporting Person was granted 60,000 Options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 5/13/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Issuer's 2023 Plan, on the Grant Date, the Reporting Person was granted 60,000 Options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 5/13/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":60000,"derivative":{"exercise_price":0.195,"expiration_date":"2034-06-17","underlying":"Common stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001493152-24-024598","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224024598/ownership.xml","form_type":"4"}},{"id":1473365,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":89728,"kind":"person","name":"Campbell Wendy Pizarro","position":1,"cik":"0001990445","reported_name":"Campbell Wendy Pizarro","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Admin. and Legal Officer"}}],"security":"Stock Options (right to buy)","published_at":"2024-06-21T00:56:02.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":40000,"derivative":{"exercise_price":0.195,"expiration_date":"2034-06-17","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-24-024598","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224024598/ownership.xml","form_type":"4"}},{"id":1473364,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21679,"kind":"person","name":"Jackson Andrew C.","position":1,"cik":"0001636738","reported_name":"Jackson Andrew C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2024-06-21T00:56:01.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 300,000 incentive stock options (the \"Options\") at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 10/30/2023, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 300,000 incentive stock options (the \"Options\") at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 10/30/2023, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":300000,"derivative":{"exercise_price":0.195,"expiration_date":"2034-06-17","underlying":"Common stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001493152-24-024599","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224024599/ownership.xml","form_type":"4"}},{"id":1473502,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":89734,"kind":"person","name":"Minev Boris Radoslavov","position":1,"cik":"0001990402","reported_name":"Minev Boris Radoslavov","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Stock Options (right to buy)","published_at":"2024-06-20T20:56:04.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":31360,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 31,360 incentive stock options (the \"Options\") at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 9/13/2023. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on June 17, 2024 (the \"Grant Date\"), the Reporting Person was granted 31,360 incentive stock options (the \"Options\") at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 9/13/2023. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":31360,"derivative":{"exercise_price":0.195,"expiration_date":"2034-06-17","underlying":"Common stock","underlying_shares":31360},"source":{"system":"sec-edgar","filing":"0001493152-24-024600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1990402/000149315224024600/ownership.xml","form_type":"4"}},{"id":1490250,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":548000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F6","text":"Represents Series D warrants to purchase up to an aggregate of 548,000 shares of common stock at an exercise price of $0.30 per share (the \"Series D Warrants\") pursuant to the Inducement Agreement. The Series D Warrants will be initially exercisable upon receipt of stockholder approval as may be required by the rules of the NYSE American and will have a term of 66 months from the Issuance Date. The Series D Warrants were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents Series D warrants to purchase up to an aggregate of 548,000 shares of common stock at an exercise price of $0.30 per share (the \"Series D Warrants\") pursuant to the Inducement Agreement. The Series D Warrants will be initially exercisable upon receipt of stockholder approval as may be required by the rules of the NYSE American and will have a term of 66 months from the Issuance Date. The Series D Warrants were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents Series D warrants to purchase up to an aggregate of 548,000 shares of common stock at an exercise price of $0.30 per share (the \"Series D Warrants\") pursuant to the Inducement Agreement. The Series D Warrants will be initially exercisable upon receipt of stockholder approval as may be required by the rules of the NYSE American and will have a term of 66 months from the Issuance Date. The Series D Warrants were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":548000,"derivative":{"exercise_price":0.3,"expiration_date":"2029-12-03","underlying":"Common Stock","underlying_shares":548000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490249,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":true,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F4","text":"Represents the exercise of 375,000 Series C warrants for 375,000 Series C Units, consisting of an aggregate of (i) 375,000 shares of common stock and (ii) Series C-1 Warrants to purchase up to an aggregate of 375,000 shares of common stock. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024."},{"field":"security","element":"securityTitle","label":"F5","text":"The Series C-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from the Issuance Date at a reduced exercise price of $0.20."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series C-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from the Issuance Date at a reduced exercise price of $0.20."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series C-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from the Issuance Date at a reduced exercise price of $0.20."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":375000,"derivative":{"exercise_price":0.2,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490248,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":false,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F4","text":"Represents the exercise of 375,000 Series C warrants for 375,000 Series C Units, consisting of an aggregate of (i) 375,000 shares of common stock and (ii) Series C-1 Warrants to purchase up to an aggregate of 375,000 shares of common stock. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024."},{"field":"security","element":"securityTitle","label":"F5","text":"The Series C-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from the Issuance Date at a reduced exercise price of $0.20."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the exercise of 375,000 Series C warrants for 375,000 Series C Units, consisting of an aggregate of (i) 375,000 shares of common stock and (ii) Series C-1 Warrants to purchase up to an aggregate of 375,000 shares of common stock. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents the exercise of 375,000 Series C warrants for 375,000 Series C Units, consisting of an aggregate of (i) 375,000 shares of common stock and (ii) Series C-1 Warrants to purchase up to an aggregate of 375,000 shares of common stock. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.2,"expiration_date":"2024-08-18","underlying":"Series C Unit","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490247,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":true,"shares":173000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"security","element":"securityTitle","label":"F3","text":"The Series B-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from June 3, 2024 (the \"Issuance Date\") at a reduced exercise price of $0.20."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from June 3, 2024 (the \"Issuance Date\") at a reduced exercise price of $0.20."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from June 3, 2024 (the \"Issuance Date\") at a reduced exercise price of $0.20."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":173000,"derivative":{"exercise_price":0.2,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":173000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490246,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":false,"shares":173000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"security","element":"securityTitle","label":"F3","text":"The Series B-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from June 3, 2024 (the \"Issuance Date\") at a reduced exercise price of $0.20."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":202000,"derivative":{"exercise_price":0.2,"expiration_date":"2025-04-18","underlying":"Series B Unit","underlying_shares":173000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490245,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":true,"shares":375000,"price":0.2,"value":75000.0,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":963887,"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490244,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":true,"shares":173000,"price":0.2,"value":34600.0,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":588887,"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1537644,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-04-22T21:00:39.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 375,000 shares of common stock acquired by the Reporting Person at the public offering price of $0.40 per Common Stock Unit, each consisting of: (i) one share of common stock, (ii) one Series A warrant, (iii) one Series B warrant, and (iv) one Series C warrant, for a total purchase price of $150,000, in connection with the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"). The Units were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"security","element":"securityTitle","label":"F4","text":"Represents 375,000 Series C warrants to purchase 375,000 Series C Units (the \"Series C Warrants\"), at an exercise price of $0.60 per Series C Unit, with each Series C Unit consisting of (i) one share of the common stock and (ii) one Series C-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series C-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024, the date of issuance of the Series C Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents 375,000 Series C warrants to purchase 375,000 Series C Units (the \"Series C Warrants\"), at an exercise price of $0.60 per Series C Unit, with each Series C Unit consisting of (i) one share of the common stock and (ii) one Series C-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series C-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024, the date of issuance of the Series C Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents 375,000 Series C warrants to purchase 375,000 Series C Units (the \"Series C Warrants\"), at an exercise price of $0.60 per Series C Unit, with each Series C Unit consisting of (i) one share of the common stock and (ii) one Series C-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series C-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024, the date of issuance of the Series C Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":375000,"derivative":{"exercise_price":0.6,"expiration_date":"2024-08-18","underlying":"Series C Unit","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-015572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015572/ownership.xml","form_type":"4"}},{"id":1537643,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-04-22T21:00:39.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 375,000 shares of common stock acquired by the Reporting Person at the public offering price of $0.40 per Common Stock Unit, each consisting of: (i) one share of common stock, (ii) one Series A warrant, (iii) one Series B warrant, and (iv) one Series C warrant, for a total purchase price of $150,000, in connection with the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"). The Units were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"security","element":"securityTitle","label":"F3","text":"Represents 375,000 Series B warrants to purchase 375,000 Series B Unit (the \"Series B Warrants\"), at an exercise price of $0.60 per Series B Unit, with each Series B Unit consisting of (i) one share of the common stock and (ii) one Series B-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series B-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024, the date of issuance of the Series B Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents 375,000 Series B warrants to purchase 375,000 Series B Unit (the \"Series B Warrants\"), at an exercise price of $0.60 per Series B Unit, with each Series B Unit consisting of (i) one share of the common stock and (ii) one Series B-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series B-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024, the date of issuance of the Series B Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents 375,000 Series B warrants to purchase 375,000 Series B Unit (the \"Series B Warrants\"), at an exercise price of $0.60 per Series B Unit, with each Series B Unit consisting of (i) one share of the common stock and (ii) one Series B-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series B-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024, the date of issuance of the Series B Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":375000,"derivative":{"exercise_price":0.6,"expiration_date":"2025-04-18","underlying":"Series B Unit","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-015572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015572/ownership.xml","form_type":"4"}},{"id":1537642,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-04-22T21:00:39.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 375,000 shares of common stock acquired by the Reporting Person at the public offering price of $0.40 per Common Stock Unit, each consisting of: (i) one share of common stock, (ii) one Series A warrant, (iii) one Series B warrant, and (iv) one Series C warrant, for a total purchase price of $150,000, in connection with the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"). The Units were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents 375,000 Series A warrants to purchase 375,000 shares of common stock at an exercise price of $0.60 per share (the \"Series A Warrants\"). The Series A Warrants are exercisable immediately upon issuance and will expire five years from April 18, 2024, the date of issuance of the Series A Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents 375,000 Series A warrants to purchase 375,000 shares of common stock at an exercise price of $0.60 per share (the \"Series A Warrants\"). The Series A Warrants are exercisable immediately upon issuance and will expire five years from April 18, 2024, the date of issuance of the Series A Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents 375,000 Series A warrants to purchase 375,000 shares of common stock at an exercise price of $0.60 per share (the \"Series A Warrants\"). The Series A Warrants are exercisable immediately upon issuance and will expire five years from April 18, 2024, the date of issuance of the Series A Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":375000,"derivative":{"exercise_price":0.6,"expiration_date":"2029-04-18","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-015572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015572/ownership.xml","form_type":"4"}},{"id":1537641,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-22T21:00:39.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0.4,"value":150000.0,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 375,000 shares of common stock acquired by the Reporting Person at the public offering price of $0.40 per Common Stock Unit, each consisting of: (i) one share of common stock, (ii) one Series A warrant, (iii) one Series B warrant, and (iv) one Series C warrant, for a total purchase price of $150,000, in connection with the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"). The Units were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":415887,"source":{"system":"sec-edgar","filing":"0001493152-24-015572","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015572/ownership.xml","form_type":"4"}},{"id":1688271,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":11808,"kind":"person","name":"Zulueta Alfonso G","position":1,"cik":"0001596336","reported_name":"Zulueta Alfonso G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-05T00:55:27.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":5644,"price":1.8,"value":10159.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date. As previously reported, Mr. Alfonso resigned as a director on November 29, 2023."}],"balance_after":133301,"source":{"system":"sec-edgar","filing":"0001493152-24-001138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224001138/ownership.xml","form_type":"4"}},{"id":1688270,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21680,"kind":"person","name":"Stewart Alan R.","position":1,"cik":"0001705492","reported_name":"Stewart Alan R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-05T00:52:55.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":7282,"price":1.8,"value":13107.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the Grant Date."}],"balance_after":54655,"source":{"system":"sec-edgar","filing":"0001493152-24-001136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224001136/ownership.xml","form_type":"4"}},{"id":1688269,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-01-05T00:51:34.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":70249,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on December 21, 2023 (the \"Grant Date\"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the \"Options\") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. The Options will vest in one year or next annual shareholder meeting, whichever first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on December 21, 2023 (the \"Grant Date\"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the \"Options\") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. The Options will vest in one year or next annual shareholder meeting, whichever first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":70249,"derivative":{"exercise_price":1.8,"expiration_date":"2033-12-21","underlying":"Common stock","underlying_shares":70249},"source":{"system":"sec-edgar","filing":"0001493152-24-001134","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224001134/ownership.xml","form_type":"4"}},{"id":1688268,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-05T00:51:34.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":10625,"price":1.8,"value":19125.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a grant of restricted stock units (\"RSUs\") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the Grant Date."}],"balance_after":27872,"source":{"system":"sec-edgar","filing":"0001493152-24-001134","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224001134/ownership.xml","form_type":"4"}},{"id":1688442,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-01-05T00:49:56.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":70249,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on December 21, 2023 (the \"Grant Date\"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the \"Options\") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. Options will vest in one year or at the next annual shareholder meeting, whichever occurs first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on December 21, 2023 (the \"Grant Date\"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the \"Options\") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. Options will vest in one year or at the next annual shareholder meeting, whichever occurs first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":70249,"derivative":{"exercise_price":1.8,"expiration_date":"2033-12-21","underlying":"Common stock","underlying_shares":70249},"source":{"system":"sec-edgar","filing":"0001493152-24-001132","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000149315224001132/ownership.xml","form_type":"4"}},{"id":1688441,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21706,"kind":"person","name":"Leftwich Scott","position":1,"cik":"0001991668","reported_name":"Leftwich Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-05T00:49:56.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":8958,"price":1.8,"value":16124.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a grant of restricted stock units (\"RSUs\") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock of $1.80. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the Grant Date."}],"balance_after":469903,"source":{"system":"sec-edgar","filing":"0001493152-24-001132","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1991668/000149315224001132/ownership.xml","form_type":"4"}},{"id":1688267,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":71434,"kind":"person","name":"Camaisa Allan","position":1,"cik":"0001990674","reported_name":"Camaisa Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President and Chairman"}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-01-05T00:49:28.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on December 21, 2023 (the \"Grant Date\"), the Reporting Person was granted 100,000 Non-Qualified Stock Options (the \"Options\") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023 in consideration of Mr. Camaisa personally guaranteeing the raising of $12,500,000 of Series B preferred stock of Calidi Biotherapeutics, a Nevada corporation (\"Old Calidi\"), in connection with the Agreement and Plan of Merger, as amended (\"Merger Agreement\"), by and among First Light Acquisition Group, Inc., FLAG Merger Sub, Inc. (\"Merger Sub\"), First Light Acquisition Group, LLC, Allan Camaisa and Old Calidi. On September 12, 2023, Merger Sub merged with and into Old Calidi, with Old Calidi surviving the merger. The options were granted in a transaction exempt under Rule 16b-3."}],"balance_after":100000,"derivative":{"exercise_price":1.8,"exercise_date":"2023-12-21","expiration_date":"2033-12-23","underlying":"Common stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-24-001131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224001131/ownership.xml","form_type":"4"}},{"id":1700211,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":95839,"kind":"person","name":"Vecchiolla Thomas A.","position":1,"cik":"0001858528","reported_name":"Vecchiolla Thomas A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T00:52:21.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":7709,"price":1.8,"value":13876.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock on December 21, 2023, of $1.80. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date."}],"balance_after":365105,"source":{"system":"sec-edgar","filing":"0001493152-23-046173","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315223046173/ownership.xml","form_type":"4"}},{"id":1781147,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":95839,"kind":"person","name":"Vecchiolla Thomas A.","position":1,"cik":"0001858528","reported_name":"Vecchiolla Thomas A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2023-09-15T01:00:10.000Z","date":"2023-09-12","kind":"other","planned":false,"acquired":true,"shares":66667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Acquired in connection with the transactions contemplated by the Merger Agreement and in satisfaction of a promissory note issued by FLAG to the Reporting Person."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Each warrant is exercisable to purchase (subject, initially, to the satisfaction of certain material conditions) one share of Class A Common Stock for $11.50 per share. The material conditions to exercise were satisfied upon the Closing, and the warrants by their terms become exercisable (including by cash settlement) 30 days following the Closing."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each warrant is exercisable to purchase (subject, initially, to the satisfaction of certain material conditions) one share of Class A Common Stock for $11.50 per share. The material conditions to exercise were satisfied upon the Closing, and the warrants by their terms become exercisable (including by cash settlement) 30 days following the Closing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each warrant is exercisable to purchase (subject, initially, to the satisfaction of certain material conditions) one share of Class A Common Stock for $11.50 per share. The material conditions to exercise were satisfied upon the Closing, and the warrants by their terms become exercisable (including by cash settlement) 30 days following the Closing."}],"balance_after":66667,"derivative":{"exercise_price":11.5,"expiration_date":"2028-09-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-23-019094","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000089924323019094/doc4.xml","form_type":"4"}},{"id":1781146,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":95839,"kind":"person","name":"Vecchiolla Thomas A.","position":1,"cik":"0001858528","reported_name":"Vecchiolla Thomas A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2023-09-15T01:00:10.000Z","date":"2023-09-12","kind":"exercise","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Acquired in connection with the transactions contemplated by the Merger Agreement and in satisfaction of a promissory note issued by FLAG to the Reporting Person."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In accordance with the Agreement and Plan of Merger, dated January 9, 2023 and as thereafter amended (the \"Merger Agreement\"), by and among First Light Acquisition Group, Inc. (\"FLAG\"), Calidi Biotherapeutics, Inc., a Nevada Corporation (\"Old Calidi\"), FLAG Merger Sub Inc., a Nevada corporation and a wholly-owned subsidiary of FLAG, First Light Acquisition Group, LLC (the \"Sponsor\"), in the capacity as representative for the stockholders of FLAG and Allan Camaisa, in the capacity as representative of the stockholders of Old Calidi, on September 12, 2023, in connection with the closing of the transactions contemplated by the Merger Agreement (the \"Closing\"), 6,000 shares of Class B common stock of FLAG directly owned by the Reporting Person converted automatically, on a one-for-one basis, into 6,000 shares of Class A common stock of FLAG. FLAG then changed its name to Calidi Biotherapeutics, Inc. (\"New Calidi\") and the Class A common stock was designated common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-23-019094","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000089924323019094/doc4.xml","form_type":"4"}},{"id":1781145,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":95839,"kind":"person","name":"Vecchiolla Thomas A.","position":1,"cik":"0001858528","reported_name":"Vecchiolla Thomas A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2023-09-15T01:00:10.000Z","date":"2023-09-12","kind":"other","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Acquired in connection with the transactions contemplated by the Merger Agreement and in satisfaction of a promissory note issued by FLAG to the Reporting Person."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Acquired in connection with the transactions contemplated by the Merger Agreement and in satisfaction of a promissory note issued by FLAG to the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."}],"balance_after":6000,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-23-019094","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000089924323019094/doc4.xml","form_type":"4"}},{"id":1781144,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":95839,"kind":"person","name":"Vecchiolla Thomas A.","position":1,"cik":"0001858528","reported_name":"Vecchiolla Thomas A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2023-09-15T01:00:10.000Z","date":"2023-09-12","kind":"exercise","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In accordance with the Agreement and Plan of Merger, dated January 9, 2023 and as thereafter amended (the \"Merger Agreement\"), by and among First Light Acquisition Group, Inc. (\"FLAG\"), Calidi Biotherapeutics, Inc., a Nevada Corporation (\"Old Calidi\"), FLAG Merger Sub Inc., a Nevada corporation and a wholly-owned subsidiary of FLAG, First Light Acquisition Group, LLC (the \"Sponsor\"), in the capacity as representative for the stockholders of FLAG and Allan Camaisa, in the capacity as representative of the stockholders of Old Calidi, on September 12, 2023, in connection with the closing of the transactions contemplated by the Merger Agreement (the \"Closing\"), 6,000 shares of Class B common stock of FLAG directly owned by the Reporting Person converted automatically, on a one-for-one basis, into 6,000 shares of Class A common stock of FLAG. FLAG then changed its name to Calidi Biotherapeutics, Inc. (\"New Calidi\") and the Class A common stock was designated common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the Agreement and Plan of Merger, dated January 9, 2023 and as thereafter amended (the \"Merger Agreement\"), by and among First Light Acquisition Group, Inc. (\"FLAG\"), Calidi Biotherapeutics, Inc., a Nevada Corporation (\"Old Calidi\"), FLAG Merger Sub Inc., a Nevada corporation and a wholly-owned subsidiary of FLAG, First Light Acquisition Group, LLC (the \"Sponsor\"), in the capacity as representative for the stockholders of FLAG and Allan Camaisa, in the capacity as representative of the stockholders of Old Calidi, on September 12, 2023, in connection with the closing of the transactions contemplated by the Merger Agreement (the \"Closing\"), 6,000 shares of Class B common stock of FLAG directly owned by the Reporting Person converted automatically, on a one-for-one basis, into 6,000 shares of Class A common stock of FLAG. FLAG then changed its name to Calidi Biotherapeutics, Inc. (\"New Calidi\") and the Class A common stock was designated common stock."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0000899243-23-019094","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000089924323019094/doc4.xml","form_type":"4"}},{"id":1781167,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":109727,"kind":"organization","name":"First Light Acquisition Group, LLC","position":1,"cik":"0001855489","reported_name":"First Light Acquisition Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109728,"kind":"person","name":"Weber William John","position":2,"cik":"0001464648","reported_name":"Weber William John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109729,"kind":"organization","name":"FLAG Sponsor Manager, LLC","position":3,"cik":"0001882920","reported_name":"FLAG Sponsor Manager, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2023-09-14T21:00:12.000Z","date":"2023-09-12","kind":"exercise","planned":false,"acquired":false,"shares":1931852,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the Agreement and Plan of Merger, dated January 9, 2023 and as thereafter amended (the \"Merger Agreement\"), by and among First Light Acquisition Group, Inc. (\"FLAG\"), Calidi Biotherapeutics, Inc., a Nevada Corporation (\"Old Calidi\"), FLAG Merger Sub Inc., a Nevada corporation and a wholly-owned subsidiary of FLAG (\"Merger Sub\"), the Sponsor, in the capacity as representative for the stockholders of FLAG and Allan Camaisa, in the capacity as representative of the stockholders of Old Calidi, on September 12, 2023, in connection with the closing of the transactions contemplated by the Merger Agreement, 1,931,852 shares of Class B common stock of FLAG directly owned by the Sponsor converted automatically, on a one-for-one basis, into 1,931,852 shares of Class A common stock of FLAG. FLAG then changed its name to Calidi Biotherapeutics, Inc. (\"New Calidi\") and the class A common stock was designated common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by First Light Acquisition Group, LLC, a Delaware limited liability company (\"Sponsor\"), FLAG Sponsor Manager, LLC, a Delaware limited liability company (\"Manager LLC\"), and William J. Weber (collectively, the \"Reporting Persons\"). Mr. Weber is the sole manager and member of Manager LLC, which is the manager of the Sponsor. Because of the relationships among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":1931852},"source":{"system":"sec-edgar","filing":"0000899243-23-019095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1882920/000089924323019095/doc4.xml","form_type":"4"}},{"id":1781166,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":109727,"kind":"organization","name":"First Light Acquisition Group, LLC","position":1,"cik":"0001855489","reported_name":"First Light Acquisition Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109728,"kind":"person","name":"Weber William John","position":2,"cik":"0001464648","reported_name":"Weber William John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109729,"kind":"organization","name":"FLAG Sponsor Manager, LLC","position":3,"cik":"0001882920","reported_name":"FLAG Sponsor Manager, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2023-09-14T21:00:12.000Z","date":"2023-09-12","kind":"other","planned":false,"acquired":false,"shares":166201,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The Sponsor forfeited the shares of Class B common stock of FLAG to FLAG for no consideration in connection with the transactions contemplated by the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Sponsor forfeited the shares of Class B common stock of FLAG to FLAG for no consideration in connection with the transactions contemplated by the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by First Light Acquisition Group, LLC, a Delaware limited liability company (\"Sponsor\"), FLAG Sponsor Manager, LLC, a Delaware limited liability company (\"Manager LLC\"), and William J. Weber (collectively, the \"Reporting Persons\"). Mr. Weber is the sole manager and member of Manager LLC, which is the manager of the Sponsor. Because of the relationships among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1931852,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":166201},"source":{"system":"sec-edgar","filing":"0000899243-23-019095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1882920/000089924323019095/doc4.xml","form_type":"4"}},{"id":1781165,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":109727,"kind":"organization","name":"First Light Acquisition Group, LLC","position":1,"cik":"0001855489","reported_name":"First Light Acquisition Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109728,"kind":"person","name":"Weber William John","position":2,"cik":"0001464648","reported_name":"Weber William John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109729,"kind":"organization","name":"FLAG Sponsor Manager, LLC","position":3,"cik":"0001882920","reported_name":"FLAG Sponsor Manager, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2023-09-14T21:00:12.000Z","date":"2023-09-12","kind":"sale","planned":false,"acquired":false,"shares":186372,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the transactions contemplated by the Merger Agreement, in order to induce investors to provide financing to New Calidi and to extinguish certain outstanding promissory notes of FLAG, the Sponsor transferred to such investors, for no cash or other payment, an aggregate of 186,372 shares of Class B common stock of FLAG."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the transactions contemplated by the Merger Agreement, in order to induce investors to provide financing to New Calidi and to extinguish certain outstanding promissory notes of FLAG, the Sponsor transferred to such investors, for no cash or other payment, an aggregate of 186,372 shares of Class B common stock of FLAG."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by First Light Acquisition Group, LLC, a Delaware limited liability company (\"Sponsor\"), FLAG Sponsor Manager, LLC, a Delaware limited liability company (\"Manager LLC\"), and William J. Weber (collectively, the \"Reporting Persons\"). Mr. Weber is the sole manager and member of Manager LLC, which is the manager of the Sponsor. Because of the relationships among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2098053,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":186372},"source":{"system":"sec-edgar","filing":"0000899243-23-019095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1882920/000089924323019095/doc4.xml","form_type":"4"}},{"id":1781164,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":109727,"kind":"organization","name":"First Light Acquisition Group, LLC","position":1,"cik":"0001855489","reported_name":"First Light Acquisition Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109728,"kind":"person","name":"Weber William John","position":2,"cik":"0001464648","reported_name":"Weber William John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109729,"kind":"organization","name":"FLAG Sponsor Manager, LLC","position":3,"cik":"0001882920","reported_name":"FLAG Sponsor Manager, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2023-09-14T21:00:12.000Z","date":"2023-09-12","kind":"sale","planned":false,"acquired":false,"shares":99388,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"kind","element":"transactionCoding","label":"F4","text":"In connection with an investment of an aggregate $12,500,000 by Jackson Investment Group, LLC (\"Jackson) in Series B Preferred Stock of Old Calidi, the Sponsor transferred 191,990 shares of Class B common stock of FLAG to Jackson on June 16, 2023, with an additional 99,388 shares of Class B common stock of FLAG transferred to Jackson on September 12, 2023 in connection with the closing of the transactions contemplated by the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with an investment of an aggregate $12,500,000 by Jackson Investment Group, LLC (\"Jackson) in Series B Preferred Stock of Old Calidi, the Sponsor transferred 191,990 shares of Class B common stock of FLAG to Jackson on June 16, 2023, with an additional 99,388 shares of Class B common stock of FLAG transferred to Jackson on September 12, 2023 in connection with the closing of the transactions contemplated by the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by First Light Acquisition Group, LLC, a Delaware limited liability company (\"Sponsor\"), FLAG Sponsor Manager, LLC, a Delaware limited liability company (\"Manager LLC\"), and William J. Weber (collectively, the \"Reporting Persons\"). Mr. Weber is the sole manager and member of Manager LLC, which is the manager of the Sponsor. Because of the relationships among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2284425,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":99388},"source":{"system":"sec-edgar","filing":"0000899243-23-019095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882920/000089924323019095/doc4.xml","form_type":"4"}},{"id":1781163,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":109727,"kind":"organization","name":"First Light Acquisition Group, LLC","position":1,"cik":"0001855489","reported_name":"First Light Acquisition Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109728,"kind":"person","name":"Weber William John","position":2,"cik":"0001464648","reported_name":"Weber William John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109729,"kind":"organization","name":"FLAG Sponsor Manager, LLC","position":3,"cik":"0001882920","reported_name":"FLAG Sponsor Manager, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2023-09-14T21:00:12.000Z","date":"2023-06-16","kind":"sale","planned":false,"acquired":false,"shares":191990,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"kind","element":"transactionCoding","label":"F4","text":"In connection with an investment of an aggregate $12,500,000 by Jackson Investment Group, LLC (\"Jackson) in Series B Preferred Stock of Old Calidi, the Sponsor transferred 191,990 shares of Class B common stock of FLAG to Jackson on June 16, 2023, with an additional 99,388 shares of Class B common stock of FLAG transferred to Jackson on September 12, 2023 in connection with the closing of the transactions contemplated by the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with an investment of an aggregate $12,500,000 by Jackson Investment Group, LLC (\"Jackson) in Series B Preferred Stock of Old Calidi, the Sponsor transferred 191,990 shares of Class B common stock of FLAG to Jackson on June 16, 2023, with an additional 99,388 shares of Class B common stock of FLAG transferred to Jackson on September 12, 2023 in connection with the closing of the transactions contemplated by the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Amended and Restated Certificate of Incorporation of FLAG, the shares of Class B common stock of FLAG had no expiration date and were automatically convertible into shares of Class A common stock of FLAG at the time of FLAG's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by First Light Acquisition Group, LLC, a Delaware limited liability company (\"Sponsor\"), FLAG Sponsor Manager, LLC, a Delaware limited liability company (\"Manager LLC\"), and William J. Weber (collectively, the \"Reporting Persons\"). Mr. Weber is the sole manager and member of Manager LLC, which is the manager of the Sponsor. Because of the relationships among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2383813,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":191990},"source":{"system":"sec-edgar","filing":"0000899243-23-019095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882920/000089924323019095/doc4.xml","form_type":"4"}},{"id":1781162,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":109727,"kind":"organization","name":"First Light Acquisition Group, LLC","position":1,"cik":"0001855489","reported_name":"First Light Acquisition Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109728,"kind":"person","name":"Weber William John","position":2,"cik":"0001464648","reported_name":"Weber William John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109729,"kind":"organization","name":"FLAG Sponsor Manager, LLC","position":3,"cik":"0001882920","reported_name":"FLAG Sponsor Manager, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2023-09-14T21:00:12.000Z","date":"2023-09-12","kind":"exercise","planned":false,"acquired":true,"shares":1931852,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the Agreement and Plan of Merger, dated January 9, 2023 and as thereafter amended (the \"Merger Agreement\"), by and among First Light Acquisition Group, Inc. (\"FLAG\"), Calidi Biotherapeutics, Inc., a Nevada Corporation (\"Old Calidi\"), FLAG Merger Sub Inc., a Nevada corporation and a wholly-owned subsidiary of FLAG (\"Merger Sub\"), the Sponsor, in the capacity as representative for the stockholders of FLAG and Allan Camaisa, in the capacity as representative of the stockholders of Old Calidi, on September 12, 2023, in connection with the closing of the transactions contemplated by the Merger Agreement, 1,931,852 shares of Class B common stock of FLAG directly owned by the Sponsor converted automatically, on a one-for-one basis, into 1,931,852 shares of Class A common stock of FLAG. FLAG then changed its name to Calidi Biotherapeutics, Inc. (\"New Calidi\") and the class A common stock was designated common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by First Light Acquisition Group, LLC, a Delaware limited liability company (\"Sponsor\"), FLAG Sponsor Manager, LLC, a Delaware limited liability company (\"Manager LLC\"), and William J. Weber (collectively, the \"Reporting Persons\"). Mr. Weber is the sole manager and member of Manager LLC, which is the manager of the Sponsor. Because of the relationships among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1931852,"source":{"system":"sec-edgar","filing":"0000899243-23-019095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882920/000089924323019095/doc4.xml","form_type":"4"}},{"id":1781143,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":106903,"kind":"organization","name":"Hudson Bay Capital Management LP","position":1,"cik":"0001393825","reported_name":"Hudson Bay Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109726,"kind":"person","name":"Gerber Sander","position":2,"cik":"0001416593","reported_name":"Gerber Sander","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock, par value $0.0001 per share","published_at":"2023-09-14T18:26:46.000Z","date":"2023-09-12","kind":"other","planned":false,"acquired":false,"shares":500000,"price":10.49,"value":5245000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Persons elected to redeem 500,000 shares of Class A Common Stock for cash."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the Reporting Persons' best estimate of the redemption price based on the Issuer's disclosure in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 21, 2023. The Reporting Persons will file and amendment to this Form 4 to the extent the actual redemption price differs in any material respect from the price reported in column (4)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by HB Strategies LLC (the \"Fund\"). Hudson Bay Capital Management LP (the \"Investment Manager\") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001393825-23-000222","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000139382523000222/primary_doc.xml","form_type":"4"}},{"id":2133633,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":81400,"kind":"organization","name":"Polar Asset Management Partners Inc.","position":1,"cik":"0001326389","reported_name":"Polar Asset Management Partners Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A common stock, par value $0.0001 per share","published_at":"2022-10-21T16:37:02.000Z","date":"2022-10-19","kind":"sale","acquired":false,"shares":36200,"price":9.9,"value":358380.0,"ownership":{"direct":false,"nature":"See footnote 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"1.\tPolar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada (the \"Reporting Person\"), serves as investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company (\"PMSMF\") and has sole voting and investment discretion with respect to the securities reported herein which are held by PMSMF.  The Reporting Person disclaims beneficial ownership of the securities reported herein, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of the securities reported herein for the purpose of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of Reporting Person's pecuniary interest therein."}],"balance_after":412800,"source":{"system":"sec-edgar","filing":"0001326389-22-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000132638922000013/primary_doc.xml","form_type":"4"}},{"id":2159474,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":109727,"kind":"organization","name":"First Light Acquisition Group, LLC","position":1,"cik":"0001855489","reported_name":"First Light Acquisition Group, LLC","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2022-09-15T00:12:54.000Z","date":"2022-09-13","kind":"sale","acquired":false,"shares":400000,"price":0.1,"value":40000.0,"ownership":{"direct":false,"nature":"See notes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Class B Common Stock have no expiration date and will automatically convert into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the sale of shares of Class B Common Stock by Sponsor, in privately negotiated transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Class B Common Stock have no expiration date and will automatically convert into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Class B Common Stock have no expiration date and will automatically convert into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by First Light Acquisition Group, LLC (\"Sponsor\"), FLAG Sponsor Manager, LLC, a Delaware limited liability Company (\"Manager LLC\"), and William J. Weber (collectively, the \"Reporting Persons\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The manager of Sponsor is FLAG Sponsor Manager, LLC (\"Manager LLC\"). William J. Weber is the sole member of Manager LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests."}],"balance_after":2575803,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000899243-22-031083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000089924322031083/doc4.xml","form_type":"4"}},{"id":2159473,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":109727,"kind":"organization","name":"First Light Acquisition Group, LLC","position":1,"cik":"0001855489","reported_name":"First Light Acquisition Group, LLC","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2022-09-15T00:12:54.000Z","date":"2022-09-12","kind":"sale","acquired":false,"shares":450000,"price":1,"value":450000.0,"ownership":{"direct":false,"nature":"See notes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Class B Common Stock have no expiration date and will automatically convert into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the sale of shares of Class B Common Stock by Sponsor, in privately negotiated transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Class B Common Stock have no expiration date and will automatically convert into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Class B Common Stock have no expiration date and will automatically convert into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by First Light Acquisition Group, LLC (\"Sponsor\"), FLAG Sponsor Manager, LLC, a Delaware limited liability Company (\"Manager LLC\"), and William J. Weber (collectively, the \"Reporting Persons\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The manager of Sponsor is FLAG Sponsor Manager, LLC (\"Manager LLC\"). William J. Weber is the sole member of Manager LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests."}],"balance_after":2874677,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000899243-22-031083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000089924322031083/doc4.xml","form_type":"4"}}]}